Clinical trial of CAR-T technology to treat blood cancer to begin soon

A team of researchers from the Indian Institute of Technology-Bombay (IIT-B) and doctors from the Tata Memorial Centre (TMC), Mumbai, will soon start the first clinical trial of indigenously developed CAR-T technology in the country for the treatment of blood cancer.

The central government’s National Biopharma Mission (NBM) -Biotechnology Industry Research Assistance Council (BIRAC) has now approved ₹18.96 crore to the team for conducting a first-in-human phase-1/2 clinical trial of the CAR-T cells. The novel CAR-T cells will act are drugs that were indigenously developed at IIT Bombay by Rahul Purwar, a professor from the Bioscience and Bioengineering (BSBE) department. The design, development, and extensive pre-clinical testing was carried out in a laboratory with clinical inputs from Dr Gaurav Narula, professor of Pediatric Oncology and Health Sciences, and his team from TMC. The team has filed for national and international patents for the product.

While the CAR-T cell technology is currently in use in developed nations with an intent to cure certain types of blood cancers, the technology is still unavailable in India. “One of the major reasons for its unavailability in India is that the drug is exorbitantly expensive. Pharmaceutical companies don’t see a market for such expensive treatments in India,” said Purwar. Two CAR-T products approved by the United States of America are Kymriah and Yescarta. However, the drugs could cost Rs5 crore per patient and could go up to ₹8 crore including hospital expenses.

The IIT Bombay and TMC team are working on reducing this cost. “A large part of the manufacturing cost goes towards skilled labour. While we are at the initial stage, we will try to bring the costs significantly down,” said Purwar. The drug is aimed at treating leukaemia and lymphoma. The BIRAC, in its statement, said that with the success of the trial, the drug will benefit cancer patients, who currently are forced to opt for palliative care.

With the grant in place, clinical trials of the novel CAR-T cells will commence at TMC. “Current treatment strategies, such as chemotherapy, are aimed at promoting life by a few months or years. They are not intended to cure cancer. The CAR-T cells have been fairly successful in this matter in some developed nations,” said Purwar. Unlike chemotherapy, this drug is administered only once to the patient.

Dr Narula said that the clinical trial of the drug will be started in a trial set up where all variables are under control. “We have received the grant to start the trial. This is one step in a long process. We will start the trial as soon as the regulators give us a go-ahead,” he said. The team is now waiting for approval from the Central Drugs Standard Control Organisation.

Source:https://www.hindustantimes.com/mumbai-news/clinical-trial-of-car-t-technology-to-treat-blood-cancer-to-begin-soon/story-1IeZ1E07a0MaIKxzVFghrI.html



Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R...
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that...
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death...
Read more